The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Increased phosphoinositide 3‐kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo
Open accessAbstract
Alterations in the cell division:cell death ratio induce multiple autoimmune and transformation processes. Phosphoinositide 3‐kinase (PI3K) controls cell division and cell death in vitro, but its effect on the function of the cellular immune system and on tumor formation in mammals is poorly characterized. Here we show that transgenic mice expressing in T lymphocytes an active form of PI3K derived from a thymic lymphoma, p65 PI3K , developed an infiltrating lymphoproliferative disorder and autoimmune renal disease with an increased number of T lymphocytes exhibiting a memory phe‐notype and reduced apoptosis. This pathology was strikingly similar to that described in mice exhibiting heterozygous loss of the tumor suppressor PTEN, a lipid and protein phosphatase. We show that overexpression of PTEN selectively blocks p65 PI3K ‐induced 3T3 fibroblast transformation. Moreover, the early development of T cell lymphomas in p65 PI3K Tg p53 _/_ mice indicated that PI3K contributes to tumor development. These observations demonstrate that constitutive activation of PI3K extends T cell survival in vivo, affects T cell homeostasis, and contributes to tumor generation, supporting a model in which selective increases in one type of PTEN substrate, the PI3K‐derived lipid products, induce tumorigenesis. PI3K thus emerges as a potential target in autoimmune disease and cancer therapy.—R.‐Borlado, L., Redondo, C., Alvarez, B., Jimenez, C., Criado, L. M., Flores, J., Marcos, M. A. R., Martinez‐A., C., Balomenos, D., Carrera, A. C. Increased phosphoinositide 3‐kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14, 895–903 (2000)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“The multiorgan T lymphocyte infiltration in p65 Tg mice was remarkable, matched only by that observed in CTLA4 mice (33, 34) and in PTEN mice (15); these latter animals exhibit a pathology very similar to that in the p65 Tg mice”
Turnover of naive- and memory-phenotype T cells.
Tough, D. F., & Sprent, J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1127 · Cited by 869 · cited 3×
“The fraction of T cells expressing the shared memory/activated CD44 CD62L CD45RB phenotype (20, 21) was increased in Tg mice compared to WT mice, as a function of age (not shown).”
Background
Cited by
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
PI3K in lymphocyte development, differentiation and activation
Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1056 · Cited by 810
Bhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance
Suzuki, A., Yamaguchi, M. T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., Yoshida, R., Wakeham, A., Higuchi, T., Fukumoto, M., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00134-0 · Cited by 589
Targeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
Immunological pathogenesis and treatment of systemic lupus erythematosus
Pan, L., Lu, M.-P., Wang, J.-H., Xu, M., & Yang, S.-R. (2020) · World Journal of Pediatrics · doi:10.1007/s12519-019-00229-3 · Cited by 411
PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?
Rommel, C., Camps, M., & Ji, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2036 · Cited by 398
PI3Kδ and primary immunodeficiencies
Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M., & Okkenhaug, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.93 · Cited by 342
PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus
Barber, D. F., Bartolomé, A., Hernandez, C., Flores, J. M., Redondo, C., Fernandez-Arias, C., Camps, M., Rückle, T., Schwarz, M. K., Rodríguez, S., et al. (2005) · Nature Medicine · doi:10.1038/nm1291 · Cited by 310
Self-citationSomatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289
Forkhead transcription factors contribute to execution of the mitotic programme in mammals
Alvarez, B., Martínez-A., C., Burgering, B. M. T., & Carrera, A. C. (2001) · Nature · doi:10.1038/35099574 · Cited by 277
Self-citationArcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
Ehninger, D., Sano, Y., de Vries, P. J., Dies, K., Franz, D., Geschwind, D. H., Kaur, M., Lee, Y.-S., Li, W., Lowe, J. K., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.115 · Cited by 120
Sester, U., Wabnitz, G. H., Kirchgessner, H., & Samstag, Y. (2007) · European Journal of Immunology · doi:10.1002/eji.200737206 · Cited by 12
Metadata
- Authors
- R.‐Borlado, L., Redondo, C., Alvarez, B., Jimenez, C., Criado, L. M., Flores, J., Marcos, M. A. R., Martinez‐A., C., Balomenos, D., & Carrera, A. C.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2000-05
- Volume
- 14
- Issue
- 7
- Pages
- 895-903
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1806127905
- Cited by
- 175
- References
- 3
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.